Authors: Matt Shirley Abstract Starting with the first-in-class agent ibrutinib, the development of Bruton tyrosine kinase (BTK) inhibitors has led to dramatic improvements in the management of B-cell malignancies.

DOI [Teaser] Key Summary Points While vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) are an essential therapeutic option in various solid tumors, post-marketing data regarding their potential cardiovascular toxicities are scant.

Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Etab Atallah (Medical College of Wisconsin, USA) discusses the current issues surrounding TKI discontinuation in CML.

Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Etab Atallah (Medical College of Wisconsin, USA) discusses the current issues surrounding TKI discontinuation in CML.

The 38% of patients who had received anticancer treatment in the 3 months prior to the COVID-19 diagnosis were categorized by type of therapy into groups that were not mutually exclusive – 20% received chemotherapy, 9% endocrine therapy, 7% VEGF inhibitors or tyrosine kinase inhibitors (TKIs), 5% immune checkpoint inhibitors (ICIs), and 3% received immunomodulators.

Among patients with metastatic clear cell renal cell carcinoma, the outcomes of second-line treatment are similar irrespective of whether they received dual immunotherapy or IO plus a tyrosine kinase inhibitor in the first line, indicates a chart review.

“Teliso-V plus erlotinib showed encouraging antitumor activity and acceptable toxicity” in patients who had previously been treated with an EGFR–tyrosine kinase inhibitor (TKI), report Ross Camidge (University of Colorado Cancer Center, Aurora, USA) and co-workers.

In this paper, we discuss the limited response of  EGFR  and  HER2  exon20ins to a wide range of standard treatment regimens, such as platinum-based chemotherapy and classic EGFR tyrosine kinase inhibitors, as well as immunotherapy.

He added that combining the multitargeted tyrosine kinase inhibitor cabozantinib – which is also a standard of care for advanced RCC – with nivolumab plus ipilimumab “has the potential to improve therapeutic outcomes in patients with metastatic RCC of intermediate and poor risk.”

Antibiotic use is associated with poor survival outcomes in people receiving tyrosine kinase inhibitors for advanced non-small-cell lung cancer or melanoma, findings indicate.

However, he pointed out that the survival curves appear to show the first signs of a possible tyrosine kinase inhibitor waning effect after treatment discontinuation in patients with stage II and IIIA disease.

The sensitivity of the selective tyrosine kinase inhibitor poziotinib in people with advanced non-small-cell lung cancer and EGFR exon 20 insertions is “highly dependent” on the location of the insertion, US researchers have found.

Individuals with non-small-cell lung cancer harboring uncommon or very rare EGFR mutations benefit from treatment with EGFR–tyrosine kinase inhibitors, but those with exon 20 insertions do not, German research suggests.

They also review the use of tyrosine kinase inhibitors as agents in the metastatic setting, as outlined in two studies ATLANTIS and COSMIC-021.

By that, I mean that an adenocarcinoma will switch to a small-cell carcinoma, and this will be the default mechanism of resistance to tyrosine kinase inhibitors.

First-line treatment with the third-generation EGFR–tyrosine kinase inhibitor aumolertinib significantly improves progression-free survival relative to gefitinib in people with advanced non-small-cell lung cancer and sensitizing EGFR mutations, indicate Chinese trial data.

The risk for neurologic adverse events is significantly lower with immune checkpoint inhibitors than with other cancer treatments, particularly chemotherapy, suggest results of a systematic review and meta-analysis.

Authors: Ana Ortega-Franco & Shereen Rafee Abstract The introduction of tyrosine kinase inhibitors (TKI) for the treatment of metastatic non-small cell lung cancer (NSCLC) harbouring sensitizing epidermal growth factor receptor (EGFR) gene mutations revolutionized the diagnostic and treatment algorithm of this subset of patients almost two decades ago.